Nuclear Translocation of the Cytoplasmic Domain of HB-EGF Induces Gastric Cancer Invasion

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Jun 1

PMID 22646534

Citations 7

Authors

Takaya Shimura

Michihiro Yoshida

Shinji Fukuda

Masahide Ebi

Yoshikazu Hirata

Tsutomu Mizoshita

Satoshi Tanida

Hiromi Kataoka

Takeshi Kamiya

Shigeki Higashiyama

Takashi Joh

Affiliations

Soon will be listed here.

Abstract

Background: Membrane-anchored heparin-binding epidermal growth factor-like growth factor (proHB-EGF) yields soluble HB-EGF, which is an epidermal growth factor receptor (EGFR) ligand, and a carboxy-terminal fragment of HB-EGF (HB-EGF-CTF) after ectodomain shedding. We previously reported that HB-EGF-CTF and unshed proHB-EGF which has the cytoplasmic domain of proHB-EGF (HB-EGF-C), translocate from the plasma membrane to the nucleus and regulate cell cycle after shedding stimuli. However, the significance of nuclear exported HB-EGF-C in human gastric cancer is unclear.

Methods: We investigated the relationship between intracellular localization of HB-EGF-C and clinical outcome in 96 gastric cancer patients treated with gastrectomy. Moreover, we established stable gastric cancer cell lines overexpressing wild-type HB-EGF (wt-HB-EGF) and mutated HB-EGF (HB-EGF-mC), which prevented HB-EGF-C nuclear translocation after shedding. Cell motility between these 2 gastric cancer cell lines was investigated using a transwell invasion assay and a wound healing assay.

Results: Of the 96 gastric cancer cases, HB-EGF-C immunoreactivity was detected in both the nucleus and cytoplasm in 19 cases (19.8 %) and in the cytoplasm only in 25 cases (26.0 %). The nuclear immunoreactivity of HB-EGF-C was significantly increased in stage pT3/4 tumors compared with pT1/2 tumors (T1/2 vs. T3/4: 11.1 % vs. 36.4 %, P < 0.01). The growth of wt-HB-EGF- and HB-EGF-mC-expressing cells significantly increased compared with control cells, but the growth of HB-EGF-mC-expressing cells was significantly decreased compared with wt-HB-EGF-expressing cells. Gastric cancer cell invasion obviously increased in wt-HB-EGF-expressing cells, but invasion in HB-EGF-mC-expressing cells showed a slight increase compared with control cells. Moreover, wt-HB-EGF overexpression increased the effectiveness of wound healing, but had no significant effect in HB-EGF-mC-expressing cells.

Conclusions: Both the function of HB-EGF as an EGFR ligand and a novel signal for HB-EGF-C nuclear translocation induce gastric cancer growth, whereas HB-EGF-C nuclear translocation independently plays a critical role in gastric cancer invasion. The present study demonstrated that HB-EGF-C nuclear translocation might be crucial in gastric cancer invasion. HB-EGF-C nuclear translocation may offer a prognostic marker and a new molecular target for gastric cancer therapy.

Citing Articles

Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in -Induced Gastric Cancer.

Baj J, Korona-Glowniak I, Forma A, Maani A, Sitarz E, Rahnama-Hezavah M Cells. 2020; 9(4).

PMID: 32340207 PMC: 7225971. DOI: 10.3390/cells9041055.

GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.

Park J, Jin M, Hur M, Nam A, Bang J, Won J Gastric Cancer. 2019; 22(5):932-940.

PMID: 30815759 DOI: 10.1007/s10120-019-00943-x.

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S J Cancer Res Clin Oncol. 2016; 143(4):573-600.

PMID: 27933395 PMC: 5352771. DOI: 10.1007/s00432-016-2308-z.

Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

Boeckx C, Blockx L, Op de Beeck K, Limame R, Van Camp G, Peeters M Am J Cancer Res. 2015; 5(6):1921-38.

PMID: 26269754 PMC: 4529614.

Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.

Zhou Z, Sharma V, Beaty B, Roh-Johnson M, Peterson E, van Rooijen N Oncogene. 2013; 33(29):3784-93.

PMID: 24013225 PMC: 3950352. DOI: 10.1038/onc.2013.363.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Adam R, Danciu T, McLellan D, Borer J, Lin J, Zurakowski D . A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res. 2003; 63(2):484-90. View

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N . Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008; 99(2):214-20. PMC: 11158050. DOI: 10.1111/j.1349-7006.2007.00676.x. View

Inui Y, Higashiyama S, Kawata S, Tamura S, Miyagawa J, Taniguchi N . Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology. 1994; 107(6):1799-804. DOI: 10.1016/0016-5085(94)90823-0. View

Marikovsky M, Breuing K, Liu P, Eriksson E, Higashiyama S, Farber P . Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A. 1993; 90(9):3889-93. PMC: 46411. DOI: 10.1073/pnas.90.9.3889. View

Singh A, Tsukada T, Zent R, Harris R . Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cells. J Cell Sci. 2004; 117(Pt 8):1365-79. DOI: 10.1242/jcs.01037. View

Wang F, Liu R, Lee S, Sloss C, Couget J, Cusack J . Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 2006; 26(14):2006-16. DOI: 10.1038/sj.onc.1209999. View

Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T . BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer. 2009; 100(8):1320-9. PMC: 2676553. DOI: 10.1038/sj.bjc.6605010. View

10.

Naef M, Yokoyama M, Friess H, Buchler M, Korc M . Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer. 1996; 66(3):315-21. DOI: 10.1002/(SICI)1097-0215(19960503)66:3<315::AID-IJC8>3.0.CO;2-1. View

11.

Nanba D, Mammoto A, Hashimoto K, Higashiyama S . Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol. 2003; 163(3):489-502. PMC: 2173632. DOI: 10.1083/jcb.200303017. View

12.

Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev I . The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011; 17(11):3619-30. DOI: 10.1158/1078-0432.CCR-10-2475. View

13.

Ongusaha P, Kwak J, Zwible A, Macip S, Higashiyama S, Taniguchi N . HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004; 64(15):5283-90. DOI: 10.1158/0008-5472.CAN-04-0925. View

14.

Normanno N, Bianco C, De Luca A, Maiello M, Salomon D . Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003; 10(1):1-21. DOI: 10.1677/erc.0.0100001. View

15.

Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, Shudou M . Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol. 2008; 180(4):763-9. PMC: 2373455. DOI: 10.1083/jcb.200710022. View

16.

Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T . Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer. 2005; 92(9):1737-45. PMC: 2362036. DOI: 10.1038/sj.bjc.6602536. View

17.

Kramer C, Klasmeyer K, Bojar H, Schulz W, Ackermann R, Grimm M . Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007; 109(10):2016-24. DOI: 10.1002/cncr.22627. View

18.

Kobrin M, Funatomi H, Friess H, Buchler M, Stathis P, Korc M . Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun. 1994; 202(3):1705-9. DOI: 10.1006/bbrc.1994.2131. View

19.

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

20.

Wang F, Sloss C, Zhang X, Lee S, Cusack J . Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res. 2007; 67(18):8486-93. DOI: 10.1158/0008-5472.CAN-07-0498. View